FibroGen Inc Provides Additional Information on Roxadustat - Conference Call Transcript
Good day, and thank you for standing by. Welcome to the FibroGen Provides Roxadustat Update Call. (Operator Instructions) And please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference to your speaker today, Michael Tung. Please go ahead.
Thank you, Victor. Good afternoon, everyone. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroGen. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; and Dr. Mark Eisner, our Chief Medical Officer. Format for today's call includes prepared remarks from Enrique and Mark. After which, we will open up the call for Q&A.
I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, statements regarding our collaboration with AstraZeneca and Astellas; results of clinical trials; our regulatory strategies and potential regulatory results; commercial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |